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Abstract Ineffective antimicrobial therapy of Pseudomonas
aeruginosa bacteraemia increases mortality. Recent studies
have proposed the use of antimicrobial combination therapy
composed of a beta-lactam with either ciprofloxacin or
tobramycin. To determine if combination therapy correlates
to lower mortality and is superior compared to monotherapy,
we investigated the effect of antimicrobial treatment regimens
on 30-day mortality in a cohort with Pseudomonas aeruginosa
bacteraemia. All cases of P. aeruginosa bacteraemia (n = 292)
in southwest Skåne County, Sweden (years 2005–2010, adult
population 361,112) and the whole county (2011–2012,
966,130) were identified. Available medical and microbiolog-
ical records for persons aged 18 years or more were reviewed
(n = 235). Antimicrobial therapy was defined as empiric at
admission or definitive after culture results and was correlated
to 30-day mortality in a multivariate regression model. The
incidence and mortality rates were 8.0 per 100,000 adults and
22.9% (67/292), respectively. As expected, multiple comorbid-
ities and high age were associated with mortality. Adequate
empiric or definitive antipseudomonal treatment was associat-
ed with lower mortality than other antimicrobial alternatives
(empiric p = 0.02, adj. p = 0.03; definitive p < 0.001, adj.
p = 0.007). No difference in mortality was seen between
empiric antipseudomonal monotherapy or empiric combina-
tion therapy. However, definitive combination therapy includ-
ing ciprofloxacin correlated to lower mortality than monother-
apy (p = 0.006, adj. p = 0.003), whereas combinations includ-
ing tobramycin did not. Our results underline the importance of
adequate antipseudomonal treatment. These data also suggest
that P. aeruginosa bacteraemia should be treated with an anti-
microbial combination including ciprofloxacin when
susceptible.
Abbreviations
AIDS Acquired immune deficiency syndrome
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Bacteraemia caused by the opportunist Pseudomonas
aeruginosa is a serious condition that has increased in inci-
dence [1]. It is associated with high age, multiple comorbidi-
ties and advanced or prolonged healthcare [1]. Hence, the
incidence rate of P. aeruginosa bacteraemia is likely to con-
tinue to rise as healthcare services are advancing and life ex-
pectancy continues to increase [1, 2]. It is one of the most
common Gram-negative bloodstream infections (BSI), only
preceded by Escherichia coli and Klebsiella spp. However,
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the mortality of P. aeruginosa BSI has consistently been re-
ported to be higher than that of E. coli BSI (23–36%) [1, 3–8].
Treatment of pulmonary infections caused by P. aeruginosa
has been the topic of several reviews [9–11]. Patients with
cystic fibrosis (CF) are often colonised by P. aeruginosa, but
it is rare that CF patients suffer from bacteraemia [12].
Pseudomonas aeruginosa also occasionally colonises chronic
wounds and the gastrointestinal and urinary tracts, particularly
in hospitalised patients or patients with indwelling catheters
[13]. Pseudomonas strains causing long-term colonisation of
CF patients have adapted to become less virulent, but are ex-
tremely resistant to antimicrobials due to altered efflux pumps,
porins, beta-lactamases with extended substrate specificity and
biofilm formation [14]. On the other hand, invasive isolates are
generally more susceptible to antimicrobials, although strains
with extensive antimicrobial resistance have been reported
[15]. The optimal antimicrobial treatment regimens against
P. aeruginosa in the airway may, thus, differ from optimal
treatment regimens against bacteraemia and conclusions drawn
from studies on pneumonia may not be generalisable to
bacteraemia.
The most adequate treatment regimen of P. aeruginosa
bacteraemia is a matter of debate. Despite the species being
often highly resistant to antimicrobials, there are normally still
several antimicrobial treatment regimens to choose from, ei-
ther as monotherapy or combination therapy. Ineffective em-
piric antimicrobial therapy has been associated with increased
mortality [16, 17]. Commonly used antipseudomonal drugs
include penicillins with beta-lactamase inhibitors, certain
cephalosporins, carbapenems, colistin, fluoroquinolones and
aminoglycosides. Combination therapy is often administered
to critically ill patients and most combinations include a beta-
lactam antimicrobial together with either a fluoroquinolone or
an aminoglycoside. Several studies have addressed the ques-
tion as to whether to use monotherapy or combination therapy
and the conclusions drawn are conflicting [16–20]. The as-
sumption that combination therapy including either
fluoroquinolones or aminoglycosides would have an equiva-
lent effect on P. aeruginosa bacteraemia is, however, not nec-
essarily correct. Earlier studies are inconclusive due to the
insufficient number of patients in each group or stratification
into combined groups of both fluoroquinolones and amino-
glycosides. Hence, the effect on bacteraemia of adding a flu-
oroquinolone or an aminoglycoside to a beta-lactam is unclear
at present.
We investigated the effect on 30-day mortality of different
antimicrobial treatment regimens against P. aeruginosa
bacteraemia.We observed that both empiric therapy on admis-
sion and definitive therapy after culture results affected mor-
tality. Combination therapy with a beta-lactam and ciproflox-
acin was significantly associated with a lower mortality com-
pared to monotherapy. Moreover, the design of our
population-based retrospective cohort allowed us to observe
unbiased incidence rates and antimicrobial susceptibility
patterns.
Materials and methods
Study population and setting
The cohort comprised the adult population (aged ≥18 years) of
southwest Skåne County, Sweden during a 6-year period
(2005–2010; adult population 361,112) in addition to the en-
tire county during a period of 2 years (2011–2012; adult pop-
ulation 966,130). The area corresponded to the catchment area
of the microbiological laboratory inMalmö that was expanded
in 2011 because of fusion with an adjacent laboratory. The
included laboratories analysed 100% of the blood cultures
sampled in the area. Hospital care was provided by Skåne
University Hospital and surrounding regional hospitals.
Participants, study protocol and variables
We identified 292 unique individuals with P. aeruginosa
bacteraemia. Recurrent cases were only included once.
Incidence rates were calculated using yearly population data
collected from Statistics Sweden [21]. Microbiological cul-
ture data were collected from the laboratory’s records
(wwLab;Autonik, Sköldinge, Sweden).Data on susceptibil-
ity and concurrent infectionswere collected, aswere the time
and date of preliminary and definitive culture results.
Clinical datawere collected from the hospital patient records
(Melior; Siemens Healthcare Services, Upplands Väsby,
Sweden). Thirty-day mortality was analysed as the outcome
variable for all study cases (n = 292), as presented graphical-
ly in Fig. 1. Patients with available hospital medical records
were included for correlations with comorbidities (n = 235).
Sixteen patients had incomplete medication charts and were
excluded from correlations with treatments (n = 219).
Missing data were missing at random, with more missing
records during the first years of the study, gradually decreas-
ing over the study period. Randomness was controlled by
comparing sex and age for missing and non-missing files.
All recorded clinical variables and healthcare-related data
are presented in the supplementary data, Table A1. The
Charlson comorbidity index (CCI) was calculated to esti-
mate the level of illness prior to the current bacteraemia
(supplementary data, Table A2) [22]. Compound variables
included pulmonary disease [chronic obstructive pulmonary
disease (COPD), pulmonary fibrosis, asthma and cystic fi-
brosis] and heart disorder (congestive heart failure, ischae-
mic heart disease, cardiac arrhythmia and heart valve
disease).
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Microbiological definitions and methods
Pseudomonas aeruginosa bacteraemia was defined as the iso-
lation of the bacterial species in a blood culture collected from
a patient at a hospital out-patient unit, a hospital ward or an
emergency department using standard aseptic techniques. The
term ‘bacteraemia’ was considered to be equivalent to BSI.
All samples were cultured using the automated BacT/ALERT
system (bioMérieux, Marcy l’Etoile, France). Isolates were
identified by typical characteristics on agar plates and bio-
chemical tests. Antimicrobial resistance was determined by
disc diffusion on Mueller–Hinton agar plates, Etests
(Biodisk, Solna, Sweden) or Vitek (bioMérieux) and subject-
ed to antimicrobial susceptibility testing according to guide-
lines from the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) [23]. Physicians were noti-
fied when preliminary results on positive blood cultures were
available.
Antimicrobial treatment
Empiric therapy was defined as antimicrobial therapy admin-
istered from 8 h before sampling of the initial blood culture to
the time the preliminary culture result was available.
Antimicrobial treatment was classified as antipseudomonal if
it included any of the following: ceftazidime, imipenem,
meropenem, ciprofloxacin, piperacillin, colistin or
combinations including gentamicin or tobramycin. Definitive
therapy was defined as antimicrobial therapy given after pre-
liminary or final culture results. Administered antimicrobials
were compared with obtained antibiograms and classified as
adequate if the bacterium was susceptible to the given drug in
question.
Statistical analysis
All data were entered into an Excel spreadsheet (Microsoft,
Redmond, WA) and exported to SPSS Statistics version 23
(IBM, Armonk, NY) and Stata 14 (StataCorp, College
Station, TX) for statistical analysis. Graphs were drawn in
Prism 6 (GraphPad, La Jolla, CA). The results were expressed
as median and interquartile range for continuous variables and
as frequencies and percentages for categorical variables. Two-
tailed p-values were calculated with Wilcoxon’s and Fisher’s
exact test and values ≤0.05 were considered statistically sig-
nificant. Odds ratios (ORs) were determined in the univariate
analysis and presented with 95% confidence intervals (CIs).
The adjusted OR for mortality was determined in a multivar-
iate logistic regression model. We used stepwise backward
selection to create the multivariable model in which all vari-
ables with p-values of ≤0.1 were entered, and variables with
resulting p-values exceeding 0.2 were excluded. Age was
stratified into categories, with 18–49 years as the index. A
propensity score-adjusted analysis was performed that includ-
ed the following covariates: age, sex, pulmonary, cardiovas-
cular, renal, hepatic, neurological and malignant comorbidi-
ties, together with healthcare indicators: catheters, surgery,
intensive care and coinfections. The propensity scores of re-
ceiving ciprofloxacin as combination therapy as well as
monotherapy were each introduced into separate logistic re-
gression models using ciprofloxacin treatment as a binary re-
gression variable.
Results
The incidence of P. aeruginosa BSI increases with high age
and male sex
The average annual incidence rate of P. aeruginosa
bacteraemia was 8.0 [standard deviation (SD) ± 1.22] cases
per 100,000 adult inhabitants. The median age of the study
cases was 74 years, well above the median age of the adult
population (47 years, Fig. 2a) and the calculated incidence rate
was highest for the oldest age groups (age ≥80 years: 31.0/
100,000 adult inhabitants). As seen in previous studies, the
incidence was higher for males than females (Fig. 2b) [5].
The most common infection focus was the urinary tract (94/
235, 40.7%), followed by the respiratory tract (42/235,
18.2%), wounds (38/235, 16.5%) and intravenous catheters
292 unique cases with P. aeruginosa 
BSI were included for calculation of
incidence rates and correlations of
age, sex and microbiological data to
30-day mortality.
In 235 cases, correlations were 
made between comorbidities and 
30-day mortality.
The effect of empirical antibiotic
treatment on 30-day mortality was 
analysed for 219 cases.
203 cases were included for analysis 
of definitive antibiotic treatment and 
30-day mortality.
57 cases had incomplete 
hospital medical records.
16 cases had incomplete 
medication charts.
16 cases died before 
culture results.
Fig. 1 Patients included in this study. Flow chart summarising the
number of cases in the present study and the reason for exclusion for
some analyses
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(9/235, 3.9%). The remaining individuals (48, 20.8%) had
unknown infection site. Urinary tract focus was more com-
mon among men (males 77/159, 49.3% vs. females 17/75,
22.6%, p < 0.001) and most men with this focus had had a
urinary catheter for more than one week (51/77, 66.2% vs.
other foci 18/61, 22.8%, p < 0.001). During the first five years
of the study, a yearly increase was seen in incident cases. This
trend, however, ceased in 2010 and, in total, we could not
observe any significant change in incidence rate, although
the number of analysed blood cultures increased throughout
the study period (Fig. 2c).
Comorbidities, high age and respiratory tract focus
correlate to increased mortality
The overall 30-day mortality for the study population was
22.9% (67/292). As expected, the surviving population was
younger (mean age 69.8 vs. 74.4 years, p = 0.02). Basic de-
mographic data, comorbidities and healthcare-related data of
all included patients are presented in Table 1. To assess the
effect of multiple comorbidities, we calculated the CCI from
age and comorbidities. The CCI and selected variables were
correlated to 30-day mortality in univariate and multivariate
regression analysis (Table 2). Females had a higher mortality
rate than males (adj. p = 0.006) and a higher CCI correlated
strongly to higher 30-day mortality (survivors mean CCI 6.9
vs. non-survivors 8.5, p = 0.002). Pulmonary, haematological
or metastatic malignant diseases were significantly associated
with high 30-day mortality, whereas recent chemotherapy or
diabetes mellitus correlated with lower 30-day mortality.
Infection focus in the respiratory tract was associated with
higher mortality and urinary tract infection or the presence
of a urinary catheter with lower mortality. Coinfection with
other pathogens was detected in 90 (31%) cases. The most
common copathogens were Enterobacteriaceae but also a di-
verse flora of enterococci, staphylococci and anaerobes were
recorded. Coinfections were associated with increased 30-day
mortality (p = 0.02). Nosocomial infection defined as being a
resident at a nursing home or being hospitalised for more than
one week before blood culture was not associated with in-
creased mortality rates.
Antimicrobial resistance against P. aeruginosa did not
increase during the study period
Antimicrobial resistance was generally low for the studied
bacterial strains compared to previous studies. Imipenem re-
sistance was 6.8%, meropenem 6.3%, piperacillin–tazobac-
tam 6.2%, tobramycin 0.7%, ceftazidime 5.5% and ciproflox-
acin 10.0%. Except for a peak in meropenem resistance in
2008, the antimicrobial resistance did not increase during the
study period (supplementary data, Table A3). In univariate
correlations, only meropenem resistance was associated with
increased 30-day mortality (6 fatalities from 13 cases, 46.2%,
p = 0.033).



































































































Fig. 2 Pseudomonas aeruginosa bacteraemia incidence increases with
age. Incident cases of P. aeruginosa bacteraemia were older (a, bars, left
y-axis) than the population in Skåne County (a, curve, right y-axis). In all
age groups, the incidence ofP. aeruginosa bacteraemia was higher among
males than females and increased with higher age (b). No increase in
incidence was seen over the entire study period (c, left y-axis), even
though the number of analysed blood cultures increased (c, right y-axis)
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Empiric antimicrobial treatment and importance
for mortality
Of the 219 patients with complete medication charts, almost
all patients (93.2%) received antimicrobial treatment after cul-
tures were drawn. In 47.5%, adequate empirical antimicrobial
agents were given according to the antibiograms. The most
common empiric treatment was cefotaxime (36.5%), followed
by tobramycin (18.3%) and piperacillin (16.9%). The empiric
use of any other antimicrobial was less than 10%. The admin-
istration of tobramycin was, in all cases, combined with an-
other antimicrobial. Monotherapy was given to 125 patients
(57.1%) and 79 patients received combination therapy
(36.1%).
The choice of empiric treatment was associated with 30-
day mortality in our cohort in direct correlations and when
entered into a multivariable regression model (Table 3, upper
section). Treatment with any effective antipseudomonal sig-
nificantly decreased the 30-day mortality to 15.4% (adj.
p = 0.03). In contrast, an increased 30-day mortality (53.3%;
adj. p = 0.01) was observed when antimicrobials were not
administered. Forty cases (18.2%) received empiric combina-
tion treatment including tobramycin, which did not decrease
the mortality rate compared to monotherapy. Only five cases
(2.3%) received empirical combination therapy including
ciprofloxacin.
Definitive antimicrobial therapy with ciprofloxacin
combinations increases survival
Sixteen patients (7.3%) died before any culture results
were available. All surviving patients (n = 203) were ad-
ministered definitive antimicrobial treatment following
positive blood culture results with P. aeruginosa. The ma-
jority of cases (174; 85.7%) were given an effective
antipseudomonal treatment. Preliminary culture results
were provided for 93.1% and the mean time to prelimi-
nary culture result was 1.96 days (SD ± 1.19) and
3.68 days (SD ± 1.63) to final results. More than half were
treated with ciprofloxacin (50.7%), as a part of a combi-
nation therapy (38.4%) or as monotherapy (12.3%).
Piperacillin–tazobactam was given to 33.0%, carbapenem
to 21.2%, tobramycin to 17.2% and, finally, ceftazidime
to 10.3% of the cases. Other antimicrobial regimens were
administered to less than 10% of patients.
The choice of an adequate definitive antipseudomonal
treatment matching the antibiogram significantly decreased
30-day mortality (adj. p = 0.007) when analysed in our multi-
variable regression model (Table 3; lower section). Targeted
monotherapy was not significantly associated with decreased
30-day mortality, whereas inadequate treatment with cefotax-
ime or cefuroxime as monotherapy increased mortality up to
40% (4/10).
In contrast to any individual monotherapy, definitive
combination therapy with ciprofloxacin decreased the
30-day mortality (adj. p = 0.003), whereas combinations
including tobramycin did not affect the mortality. To dis-
close involuntary selection bias in the group receiving
ciprofloxacin, a propensity score was calculated. The ef-
fect of the addition of ciprofloxacin was independent of
confounders (age, sex, comorbidities and intensive care
treatment, as well as choice of antimicrobial agent).
With the available covariates, we did not find any evi-
dence of selection bias to any of the ciprofloxacin/no cip-
rofloxacin groups. Propensity score-adjusted analyses did
not change the effect on mortality for ciprofloxacin com-
bination therapy (propensity score-adjusted OR 0.16, 95%
CI 0.05–0.53, p = 0.003 vs. OR 0.16, 95% CI 0.05–0.53,
p = 0.003). For ciprofloxacin monotherapy, the association
remained non-significant (propensity score-adjusted OR
0.59, 95% CI 0.04–9.9, p = 0.72 vs. OR 0.32, 95% CI
0.06–1.83, p = 0.20). The lower mortality associated with
ciprofloxacin combination therapy was independent of
Table 1 Basic demographic data of cases in this study
Characteristic Male (n = 159) Female (n = 76)
Age 74 (63–80) 74 (63–83)
Charlson score 7 (5–9) 6 (5–9)
Pulmonary disease* 34 (21.4) 15 (19.7)
COPD 17 (10.7) 7 (9.2)
Cystic fibrosis 1 (0.6) 0 (0.0)
Heart disorder* 62 (39.0) 25 (32.9)
Peripheral vascular disease 40 (25.2) 15 (19.7)
Vascular graft 11 (6.9) 4 (5.3)
Diabetes mellitus 50 (31.4) 22 (28.9)
Renal failure 36 (22.6) 6 (7.9)
Chronic liver disease 4 (2.5) 4 (5.3)
Neurological paresis 4 (2.5) 0 (0.0)
Immunosuppression 35 (22.0) 17 (22.4)
Chemotherapy in the last 6 months 30 (18.9) 22 (28.9)
Solid malignancy 45 (28.3) 28 (36.8)
Metastasis 24 (15.1) 15 (19.7)
Haematological disease 26 (16.4) 10 (13.2)
Neutropaenia 24 (15.1) 14 (18.4)
AIDS 1 (0.6) 0 (0.0)
Burn wounds 4 (2.5) 2 (2.6)
Urinary catheter >1 week 70 (44.0) 18 (23.7)
Hospitalised >1 week 58 (36.5) 24 (31.6)
Surgery in the last month 34 (21.4) 14 (18.4)
Resident at nursing home 26 (16.4) 7 (9.2)
Age for all cases (n = 292) and characteristics for cases with full medical
records (n = 235). Continuous variables are expressed as median (inter-
quartile range) and categorical variables as observed numbers (percent-
age). Compound variables are marked with *
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age, CCI and origin of infection (Fig. 3a–c). Importantly
also, patients in intensive care units that were treated with
ciprofloxacin had a lower 30-day mortality than those
receiving other antimicrobials (0 dead of 9 treated: 0%
vs. other: 7/19, 36.8%, adj. p = 0.035).
Discussion
In this retrospective cohort study, we provide evidence that the
choice of antimicrobial treatment affected the 30-day mortal-
ity in patients suffering from P. aeruginosa bacteraemia.
Table 2 Thirty-day mortality correlated to selected characteristics
Characteristic (n = 292) n Died (%) OR (95% CI) p-value adj. OR (95% CI) adj. p-value
Male sex 201 40 (19.9) 0.59 (0.33–1.04) 0.07 0.35 (0.17–0.74) 0.006
Age 18–49 years 22 2 (9.1) 1.00
Age 50–59 years 36 6 (16.7) 2.00 (0.37–10.92) 0.42 2.72 (0.39–19.08) 0.31
Age 60–69 years 62 14 (22.6) 2.92 (0.61–14.03) 0.18 3.21 (0.51–20.03) 0.21
Age 70–79 years 83 20 (24.1) 3.17 (0.68–14.78) 0.14 3.58 (0.58–22.17) 0.17
Age ≥80 years 89 25 (28.1) 3.91 (0.85–17.95) 0.08 6.60 (1.13–38.49) 0.04
Comorbidity (n = 235)
Pulmonary disease 49 18 (36.7) 2.58 (1.29–5.14) 0.01 3.05 (1.34–6.94) 0.008
COPD 24 8 (33.3) 1.89 (0.76–4.69) 0.20 0.61 (0.16–2.37) 0.47
Cystic fibrosis 1 0 (0.0)
Heart disorder 87 22 (25.3) 1.33 (0.71–2.49) 0.42 1.50 (0.64–3.51) 0.35
Peripheral vascular disease 55 13 (23.6) 1.14 (0.56–2.34) 0.71 2.26 (0.96–5.30) 0.06
Vascular graft 15 1 (6.7) 0.24 (0.03–1.83) 0.20 0.18 (0.02–1.69) 0.13
Diabetes mellitus 63 9 (14.3) 0.49 (0.22–1.08) 0.08 0.46 (0.22–0.96) 0.04
Renal failure 42 10 (23.8) 1.12 (0.51–2.46) 0.84 1.96 (0.74–5.17) 0.18
Chronic liver disease 9 3 (33.3) 1.79 (0.43–7.40) 0.42 1.27 (0.22–7.21) 0.79
Neurological paresis 3 1 (33.3) 1.16 (0.12–11.36) 1.00 7.61 (0.45–128.36) 0.16
Immunosuppression 52 11 (21.2) 0.91 (0.43–1.93) 0.85 0.75 (0.26–2.18) 0.59
Chemotherapy in the last 6 months 52 12 (23.1) 1.05 (0.50–2.19) 1.00 0.21 (0.07–0.66) 0.007
Solid malignancy 73 20 (27.4) 1.55 (0.81–2.94) 0.23 0.99 (0.37–2.68) 0.98
Metastasis 39 14 (35.9) 2.33 (1.11–4.90) 0.03 7.12 (2.32–21.79) 0.001
Haematologic disease 42 11 (26.2) 1.63 (0.74–3.59) 0.28 5.47 (1.85–16.17) 0.002
Neutropaenia 38 11 (28.9) 1.51 (0.69–3.30) 0.30 1.33 (0.41–4.28) 0.63
AIDS 1 0 (0.0)
Burn wounds 6 2 (33.3) 1.77 (0.32–9.95) 0.62 4.08 (0.45–36.68) 0.21
Composite comorbidity score (n = 235)
Charlson score ≤4 44 4 (9.1) 1.00
Charlson score 5–8 119 27 (22.7) 2.93 (0.96–8.94) 0.06 2.91 (0.95–8.92) 0.06
Charlson score 9–12 49 13 (26.5) 3.61 (1.08–12.08) 0.04 3.67 (1.09–12.41) 0.04
Charlson score ≥13 21 8 (38.1) 6.15 (1.59–23.82) 0.009 7.05 (1.79–27.86) 0.005
Healthcare-related (n = 235)
Urinary catheter >1 week 88 18 (20.5) 0.87 (0.45–1.65) 0.75 1.09 (0.50–2.39) 0.82
Surgery last month 48 9 (18.8) 0.76 (0.34–1.69) 0.56 0.98 (0.38–2.51) 0.96
Hospitalised >1 week 82 20 (24.4) 1.21 (0.64–2.29) 0.62 1.61 (0.76–3.41) 0.22
Resident at nursing home 33 8 (24.2) 1.15 (0.48–2.72) 0.82 1.16 (0.41–3.32) 0.78
Polymicrobial infection 90 22 (24.4) 1.13 (0.62–2.02) 0.68 2.52 (1.18–5.40) 0.02
Origin of infection (n = 235)
Urinary tract 82 12 (14.6) 0.37 (0.18–0.75) 0.005 0.28 (0.12–0.65) 0.003
Respiratory tract 44 17 (38.6) 2.81 (1.38–5.70) 0.003 2.81 (1.13–7.01) 0.03
Wound 38 12 (31.6) 1.81 (0.84–3.90) 0.13 1.99 (0.81–4.92) 0.13
Central venous catheter 9 0 (0.0)
Other/unknown 50 11 (22.0) 0.99 (0.47–2.11) 0.98 1.16 (0.47–2.83) 0.75
Patient characteristics correlated to 30-daymortality and presented with odds ratio (OR), adjusted odds ratio (adj. OR) and 95% confidence interval (95%
CI). The multivariable model contained age, sex, pulmonary disease, vascular graft, peripheral vascular disease, chemotherapy in the last 6 months,
haematological diseases including malignancies, metastasis, diabetes mellitus and neurological paresis. Significant values are in bold font
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Despite the average time to culture results being as short as
48 h, inadequate empiric antimicrobial treatment on admission
negatively affected mortality rates. Similarly, inadequate de-
finitive treatment after blood culture results was also associat-
ed with higher mortality rates. Particularly, definitive combi-
nation treatment that included ciprofloxacin favourably affect-
ed the 30-day mortality.
In total, we identified 292 patients with P. aeruginosa
bacteraemia between 2005 and 2012. The overall 30-day mor-
tality in this study was 22.9% and the annual incidence was 8
per 100,000 inhabitants, with higher rates amongmen and with
increasing age. This was in line with previous studies, which
have reported 30-day mortality rates ranging from 23% to
36.5% and incidence rates in the range 3.6–10.8 cases per
100,000 inhabitants and year [1, 3–8]. The incidence was
higher for males than females, which was accounted for by
the higher incidence among males with urinary catheter.
Although the number of blood cultures steadily increased dur-
ing the study period, no increase in the incidence of
P. aeruginosa bacteraemia was seen over the entire study pe-
riod. However, in parallel to the increase reported in the UK,
the incidence rate in our study rose between 2005 and 2009 [1].
The explanation for the rising incidence during the first several
years of the study and the concurrent increase in the UK is, at
present, unclear and no epidemiological link is known.
The importance of correct empiric therapy on admission
has been debated and, in the present study, the initial antimi-
crobial choice was important, as patients who received ade-
quate antipseudomonal treatment had significantly lower mor-
tality rates [3, 17, 24]. No individual empirical antimicrobial
monotherapy or combination therapy was associated with
changes in mortality. The large number of different adminis-
tered antimicrobials resulted in low statistical power for all but
the most commonly used drugs and only five patients received
empirical ciprofloxacin combination treatment.
After positive blood cultures with P. aeruginosa, adequate
definitive antipseudomonal treatment decreased the 30-day
mortality. In contrast to ciprofloxacin combinations, combina-
tion therapy including tobramycin was not superior to mono-
therapy, similarly to that previously reported [20]. To find the
potential influence of selection bias on our results, a propensity
score was calculated to ensure comparability of the cohort re-
ceiving ciprofloxacin and those receiving other treatments, but
no such bias could be identified. A few previous studies have
investigated whether combination therapy was favourable
against P. aeruginosa bacteraemia. For example, Kim et al.
Table 3 The antimicrobial treatment choice influences 30-day mortality
30-Day mortality, empirical treatment (n = 219)
n Died (%) OR (95%) p-value adj. OR (95% CI) adj. p-value
Cefotaxime or cefuroxime 100 23 (23.0) 1.06 (0.56–2.00) 0.87 0.68 (0.31–1.49) 0.34
Benzylpenicillin 8 4 (50.0) 3.51 (0.85–14.42) 0.08 3.09 (0.52–18.38) 0.22
Imipenem or meropenem 34 5 (14.7) 0.55 (0.20–1.51) 0.25 0.84 (0.23–3.12) 0.79
Piperacillin–tazobactam 37 7 (18.9) 0.78 (0.32–1.90) 0.58 0.61 (0.20–1.89) 0.39
Ciprofloxacin 11 1 (9.1) 0.33 (0.04–2.64) 0.30 0.57 (0.06–5.56) 0.63
Combination including tobramycin 40 10 (25.0) 1.20 (0.54–2.66) 0.66 1.10 (0.39–3.11) 0.85
Any other combination 39 6 (15.4) 0.58 (0.23–1.48) 0.30 0.40 (0.13–1.27) 0.12
No empirical antibiotic treatment 15 8 (53.3) 4.52 (1.55–13.20) 0.007 5.84 (1.43–23.84) 0.01
Adequate antipseudomonal treatment 104 16 (15.4) 0.45 (0.23–0.88) 0.02 0.37 (0.16–0.89) 0.03
30-Day mortality, definitive treatment (n = 203)
n Died (%) OR (95% CI) p-value adj. OR (95% CI) adj. p-value
Cefotaxime or cefuroxime 10 4 (40.0) 3.93 (1.04–14.81) 0.043 5.59 (0.94–33.35) 0.06
Imipenem or meropenem 43 5 (11.6) 0.65 (0.23–1.80) 0.41 1.26 (0.35–4.49) 0.73
Piperacillin–tazobactam 67 11 (16.4) 1.05 (0.47–2.32) 1.00 1.07 (0.40–2.87) 0.89
Ceftazidime 21 1 (4.8) 0.24 (0.03–1.88) 0.18 0.19 (0.02–1.91) 0.16
Ciprofloxacin, monotherapy 25 2 (8.0) 0.43 (0.10–1.92) 0.27 0.32 (0.06–1.83) 0.20
Combination including ciprofloxacin 78 5 (6.4) 0.25 (0.09–0.68) 0.006 0.16 (0.05–0.55) 0.003
Combination including tobramycin 35 4 (11.4) 0.65 (0.21–1.97) 0.44 1.23 (0.31–4.91) 0.77
Adequate antipseudomonal treatment 174 20 (11.5) 0.17 (0.07–0.41) <0.001 0.17 (0.05–0.62) 0.007
The effect of empiric and definitive antimicrobial treatment on 30-day mortality. Correlations to 30-day mortality presented as odds ratio (OR) with 95%
confidence interval (95%CI) and p-values. Themultivariablemodel contained age, sex, lung disease, vascular graft, peripheral vascular disease, chemotherapy
in the last 6 months, metastasis, haematological disease, diabetes mellitus and neurological paresis, coinfections, treatment in the intensive care unit, tracheal
intubation and urinary catheter. Significant adjusted p-values are in bold. Treatment regimens given to less than five patients are not shown in this table
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showed that adequate combination therapy of any sort was
beneficial for a subgroup of bacteraemic patients with febrile
neutropaenia [18]. Peña et al. reported, however, that the choice
between combination therapy and single-drug therapy did not
affect outcome [17]. Furthermore, in a recent meta-analysis
focusing on empiric treatment, no difference in mortality was
seen between the study groups, but in contrast to the present
investigation, no analysis was made separately for aminoglyco-
side and ciprofloxacin combination therapy [19]. Our results
are supported by DiMondi et al., who investigated the short-
term outcome of bacteraemia and pneumonia; ciprofloxacin
combinations comprised 90% of the combination therapies that
were associated with favourable outcome [16]. Both beta-
lactams and ciprofloxacin are highly efficient against
P. aeruginosa in vitro. The reason for the favourable outcome
for ciprofloxacin combination-treated patients in the present
study is unknown. Combination therapy broadens the antimi-
crobial spectrum and synergy between antimicrobial drugs has
been described, but synergy between ciprofloxacin and beta-
lactams has not been reported [25].
In our cohort, 10.0% of the bacterial strains had reduced
susceptibility for ciprofloxacin. This should be compared to
three BSI studies from the USA that reported varying resis-
tance levels (range 4.7–31%), with the highest levels from
Maryland, where a majority of cases had been hospitalised
for more than three days at inclusion [3, 4, 24]. Local knowl-
edge of resistance levels is important, but it may be difficult to
derive current resistance levels from surveillance programmes,
as BSI may not be reported and, often, bacteraemia-causing
bacteria are more susceptible. For comparison, the fluoroquin-
olone resistance in Skåne County of P. aeruginosa bacteraemia
strains was 9.8% in 2011, whereas in the same year, 88.1% of
P. aeruginosa strains from the respiratory tract of patients with
CF were resistant to fluoroquinolones (unpublished data).
Hence, combinations of antimicrobials including ciprofloxacin
may be the most effective antipseudomonal treatment against
bacteraemia, but the results are not, however, generalisable to
pneumonia.
Patients suffering from BSI were of higher age than the
general population and hadmultiple comorbidities, which also
correlated to higher 30-day mortality, as did pulmonary dis-
ease (and infectious foci in the respiratory tract), malignant
disease with metastasis and haematological malignancies. As
inadequate antimicrobial therapy increased mortality, the like-
lihood of P. aeruginosa BSI should be considered at the
choice of empiric antimicrobial therapy. Not all septic patients
need empiric antipseudomonal treatment at admission, but it
could be considered for patients with increased risk of
Pseudomonas bacteraemia and with high risk of mortality. In
addition to critically ill patients, these results suggest that pa-
tients with neoplasia and the elderly with multiple comorbid-
ities could be eligible for such treatment. However, laboratory
tests in vitro have shown that the use of ciprofloxacin at sub-
MIC concentrations lead to bacterial mutations, causing resis-
tance against both ciprofloxacin and beta-lactam antimicro-
























































































cases had a lower 30-day
mortality. Thirty-day mortality
rates in percent after treatment
with ciprofloxacin or other
antimicrobial drug as definitive
therapy when culture results were
available. The results were
stratified by age groups (a),
comorbidity as defined by the
Charlson comorbidity index
(CCI) (b) or infection focus (c)
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be made wisely in order to limit further resistance develop-
ment and monotherapy with ciprofloxacin should probably be
avoided.
Our study cohort had a minimised population selection
bias and, consequently, allowed for observation of, in to-
tal, 4.2 million adult person-years. The records at the mi-
crobiology laboratories allowed us to identify every oc-
currence of P. aeruginosa bacteraemia. This population-
based approach allowed for a valid analysis of the inci-
dence rate. We were not able to use a scoring system for
severity of disease; instead this was determined by treat-
ment at an intensive care unit. In the future, a prospective
randomised interventional study to examine the effects of
treatment regimens would be of high value, although the
relative infrequency of P. aeruginosa bacteraemia would
make this challenging in practice. An alternative would be
a larger retrospective trial with emphasis on markers of
acute severe disease.
In conclusion, this study gives an indication that
P. aeruginosa bacteraemia should be treated with definitive
antimicrobial drug combination regimens including ciproflox-
acin when susceptible. Inadequate empiric antipseudomonal
treatment on admission or inadequate definitive therapy after
notification of positive blood cultures was associated with
increased mortality. These results are of particular importance
to those at the greatest risk for P. aeruginosa bacteraemia, the
elderly patients with multiple comorbidities and patients with
malignancy. Appropriate antipseudomonal treatment should
be considered for these patients as early as possible to mini-
mise the risk of death.
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